Free Trial
LON:IMM

ImmuPharma (IMM) Share Price, News & Analysis

ImmuPharma logo
GBX 1.20 -0.08 (-6.25%)
(As of 12/20/2024 12:01 PM ET)

About ImmuPharma Stock (LON:IMM)

Key Stats

Today's Range
1.08
1.29
50-Day Range
1.05
1.97
52-Week Range
0.82
3
Volume
2.17 million shs
Average Volume
1.81 million shs
Market Capitalization
£5.00 million
P/E Ratio
N/A
Dividend Yield
0.77%
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

IMM Stock News Headlines

Immupharma Share Chat (IMM)
How to piss off your liberal friends… and profit from it
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.
T42 Iot Track. Share Chat
5x Long Qqq Share Chat
See More Headlines

IMM Stock Analysis - Frequently Asked Questions

ImmuPharma's stock was trading at GBX 1.67 on January 1st, 2024. Since then, IMM shares have decreased by 28.1% and is now trading at GBX 1.20.
View the best growth stocks for 2024 here
.

ImmuPharma plc (LON:IMM) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($1.69) earnings per share (EPS) for the quarter.

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), MOTIF BIO PLC/S (MTFB), Nikola (NKLA), Thor Energy (THR), Aminex (AEX) and GSK (GSK).

Company Calendar

Last Earnings
9/30/2020
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
£-2,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£94,819.00
Cash Flow
GBX 0.06 per share
Book Value
GBX 1 per share

Miscellaneous

Free Float
N/A
Market Cap
£5.00 million
Optionable
Not Optionable
Beta
1.53
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (LON:IMM) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners